Generalized Pairwise Comparisons to Assess Treatment Effects : JACC Review Topic of the Week
Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved..
A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit of therapy because the severity of the events, events repeated over time, and clinically relevant nonsurvival outcomes cannot be considered. The generalized pairwise comparisons (GPC) method adds flexibility in defining the primary endpoint by including any number and type of outcomes that best capture the clinical benefit of a therapy as compared with standard of care. Clinically important outcomes, including bleeding severity, number of interventions, and quality of life, can easily be integrated in a single analysis. The treatment effect in GPC can be expressed by the net treatment benefit, the success odds, or the win ratio. This review provides guidance on the use of GPC and the choice of treatment effect measures for the analysis and reporting of cardiovascular trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:82 |
|---|---|
| Enthalten in: |
Journal of the American College of Cardiology - 82(2023), 13 vom: 26. Sept., Seite 1360-1372 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Verbeeck, Johan [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 22.09.2023 Date Revised 22.09.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jacc.2023.06.047 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM362270589 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM362270589 | ||
| 003 | DE-627 | ||
| 005 | 20231226090904.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2023.06.047 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1207.xml |
| 035 | |a (DE-627)NLM362270589 | ||
| 035 | |a (NLM)37730293 | ||
| 035 | |a (PII)S0735-1097(23)06292-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Verbeeck, Johan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Generalized Pairwise Comparisons to Assess Treatment Effects |b JACC Review Topic of the Week |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 22.09.2023 | ||
| 500 | |a Date Revised 22.09.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a A time-to-first-event composite endpoint analysis has well-known shortcomings in evaluating a treatment effect in cardiovascular clinical trials. It does not fully describe the clinical benefit of therapy because the severity of the events, events repeated over time, and clinically relevant nonsurvival outcomes cannot be considered. The generalized pairwise comparisons (GPC) method adds flexibility in defining the primary endpoint by including any number and type of outcomes that best capture the clinical benefit of a therapy as compared with standard of care. Clinically important outcomes, including bleeding severity, number of interventions, and quality of life, can easily be integrated in a single analysis. The treatment effect in GPC can be expressed by the net treatment benefit, the success odds, or the win ratio. This review provides guidance on the use of GPC and the choice of treatment effect measures for the analysis and reporting of cardiovascular trials | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a absolute treatment effect | |
| 650 | 4 | |a biostatistics | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a composite endpoints | |
| 650 | 4 | |a endpoint determinations | |
| 650 | 4 | |a generalized pairwise comparisons | |
| 650 | 4 | |a net treatment benefit | |
| 650 | 4 | |a randomized controlled trials as topic | |
| 650 | 4 | |a relative treatment effect | |
| 650 | 4 | |a success odds | |
| 650 | 4 | |a survival analysis | |
| 650 | 4 | |a win ratio | |
| 700 | 1 | |a De Backer, Mickaël |e verfasserin |4 aut | |
| 700 | 1 | |a Verwerft, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Salvaggio, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Valgimigli, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Vranckx, Pascal |e verfasserin |4 aut | |
| 700 | 1 | |a Buyse, Marc |e verfasserin |4 aut | |
| 700 | 1 | |a Brunner, Edgar |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Cardiology |d 1987 |g 82(2023), 13 vom: 26. Sept., Seite 1360-1372 |w (DE-627)NLM012608602 |x 1558-3597 |7 nnns |
| 773 | 1 | 8 | |g volume:82 |g year:2023 |g number:13 |g day:26 |g month:09 |g pages:1360-1372 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jacc.2023.06.047 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 82 |j 2023 |e 13 |b 26 |c 09 |h 1360-1372 | ||